Allogeneic CAR-T Cells: More than Ease of Access?
Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inabi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2073-4409/7/10/155 |
| _version_ | 1797717092511776768 |
|---|---|
| author | Charlotte Graham Agnieszka Jozwik Andrea Pepper Reuben Benjamin |
| author_facet | Charlotte Graham Agnieszka Jozwik Andrea Pepper Reuben Benjamin |
| author_sort | Charlotte Graham |
| collection | DOAJ |
| description | Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inability to manufacture CAR-T cells from the patient’s own T cells, disease progression and death prior to return of engineered cells. T cell dysfunction is known to occur in cancer patients, and several groups have recently described differences in CAR-T cells generated from chronic lymphocytic leukaemia (CLL) patients compared with those from a healthy donor. This is thought to contribute to the low response rate in this disease group. Healthy donor, gene-edited CAR-T cells which do not require human leucocyte antigen (HLA) matching have the potential to provide an ‘off the shelf’ product, overcoming the manufacturing difficulties of producing CAR-T cells for each individual patient. They may also provide a more functional, potent product for malignancies such as CLL, where T cell dysfunction is common and frequently cannot be fully reversed during the manufacturing process. Here we review the potential benefits and obstacles for healthy donor, allogeneic CAR-T cells. |
| first_indexed | 2024-03-12T08:31:18Z |
| format | Article |
| id | doaj.art-df9bbf08be064f14b344f2ebc06345be |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T08:31:18Z |
| publishDate | 2018-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-df9bbf08be064f14b344f2ebc06345be2023-09-02T17:43:12ZengMDPI AGCells2073-44092018-10-0171015510.3390/cells7100155cells7100155Allogeneic CAR-T Cells: More than Ease of Access?Charlotte Graham0Agnieszka Jozwik1Andrea Pepper2Reuben Benjamin3Department of Haematological Medicine, King’s College London, London SE5 9NU, UKDepartment of Haematological Medicine, King’s College London, London SE5 9NU, UKDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, University of Sussex, Falmer BN1 9PX, UKDepartment of Haematological Medicine, King’s College London, London SE5 9NU, UKPatient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inability to manufacture CAR-T cells from the patient’s own T cells, disease progression and death prior to return of engineered cells. T cell dysfunction is known to occur in cancer patients, and several groups have recently described differences in CAR-T cells generated from chronic lymphocytic leukaemia (CLL) patients compared with those from a healthy donor. This is thought to contribute to the low response rate in this disease group. Healthy donor, gene-edited CAR-T cells which do not require human leucocyte antigen (HLA) matching have the potential to provide an ‘off the shelf’ product, overcoming the manufacturing difficulties of producing CAR-T cells for each individual patient. They may also provide a more functional, potent product for malignancies such as CLL, where T cell dysfunction is common and frequently cannot be fully reversed during the manufacturing process. Here we review the potential benefits and obstacles for healthy donor, allogeneic CAR-T cells.http://www.mdpi.com/2073-4409/7/10/155CAR-T cellscancer immunotherapygene editing |
| spellingShingle | Charlotte Graham Agnieszka Jozwik Andrea Pepper Reuben Benjamin Allogeneic CAR-T Cells: More than Ease of Access? Cells CAR-T cells cancer immunotherapy gene editing |
| title | Allogeneic CAR-T Cells: More than Ease of Access? |
| title_full | Allogeneic CAR-T Cells: More than Ease of Access? |
| title_fullStr | Allogeneic CAR-T Cells: More than Ease of Access? |
| title_full_unstemmed | Allogeneic CAR-T Cells: More than Ease of Access? |
| title_short | Allogeneic CAR-T Cells: More than Ease of Access? |
| title_sort | allogeneic car t cells more than ease of access |
| topic | CAR-T cells cancer immunotherapy gene editing |
| url | http://www.mdpi.com/2073-4409/7/10/155 |
| work_keys_str_mv | AT charlottegraham allogeneiccartcellsmorethaneaseofaccess AT agnieszkajozwik allogeneiccartcellsmorethaneaseofaccess AT andreapepper allogeneiccartcellsmorethaneaseofaccess AT reubenbenjamin allogeneiccartcellsmorethaneaseofaccess |